Task: Answer Verification
Input (English): Question: Is relapse risk after autologous transplantation in patients with newly diagnosed myeloma related with infused tumor cell load and the outcome is not improved by CD34+ cell selection : long term follow-up of an EBMT phase III randomized study?
Answer: Despite significant tumor cell reduction, CD34+ selection does not reduce RR and increases the risk of severe post-transplant infections. There was also no difference in RR between patients in either arm who received grafts with detectable tumor cells and those receiving grafts with no detectable tumor cells, suggesting that reinfused tumor cells may not be the main cause of relapse after autologous transplant in myeloma.
Output (English): no